AI-generated analysis. Always verify with the original filing.
Glucotrack, Inc. announced financial results for the year ended December 31, 2025, reporting a reduced net loss of $19.4 million and cash position of $7.4 million, alongside progress on implantable CBGM technology and $4.0 million private placement.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Current Report on Form 8-K and the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securiti
Financial Statements and Exhibits** (d) Exhibits | Exhibit No. | | Description | |---|---|---| | 99.1 | | Press Release, dated March 30, 2026 | | 104 | | Cover
| Metric | Value | Basis |
|---|---|---|
| Research and Development Expenses | $9.8K | GAAP |
| General and Administrative Expenses | $6.3K | GAAP |
| Net Loss | $19.4K | GAAP |
| Basic and Diluted Loss per Share | $31.22 | GAAP |